ABSTRACT
INTRODUCTION

Regulatory background
There are three categories for human medicines in the United Kingdom (UK), namely prescription-only medicines (POM), pharmacy-only (P) medicines and general sales list (GSL) medicines. POM medicines are only available on prescription, while P medicines can be sold from a pharmacy under the supervision of a pharmacist. In contrast, GSL medicines can be sold from most retail outlets. 1, 2 Over-the-counter (OTC) medicines is a collective term used to describe P and/or GSL medicines that can be purchased without a prescription although in this paper it is used exclusively to indicate supply from a community pharmacy.
The main determinant of a medicine's legal status is its safety, although factors such as side effects, monitoring requirements, route of administration, liability to misuse and risk to human health are also considered. 2 When a medicine is 'switched' from one legal category to another this is termed reclassification. Reclassification from POM to P is associated with benefits for the patient 3, 4, 5 , government 6, 7, 8 , pharmacy profession 9 and drug industry. 10 Whether such reclassification is appropriate for an antimicrobial agent is unclear.
Ophthalmic chloramphenicol
Ophthalmic chloramphenicol was the first antibiotic available for purchase OTC in the UK and was indicated for the treatment of acute bacterial conjunctivitis. The eye drops were marketed in June 2005 and the ointment in July 2007, both as P medicines. The drug is routinely prescribed by primary care prescribers 11 for suspected cases of infective conjunctivitis and is the recommended first-line treatment. 12 Prior to OTC availability, community pharmacists were limited to selling antiseptic preparations such as propamidine and dibrompropamidinebased products for ophthalmic infections. 13 The proposal to make ophthalmic chloramphenicol available OTC was welcomed by various groups of healthcare professionals and the public following widespread consultation. At the time the benefit of improved and timely access to treatment outweighed the risks associated with wider accessibility 14, 15 , although concerns regarding inappropriate over-supply, misdiagnosis by pharmacists and the emergence of increased bacterial resistance were raised. 16 
Recent findings
Since the launch of OTC ophthalmic chloramphenicol two main issues have come to light.
First, pharmacy availability of ophthalmic chloramphenicol has been shown to have no impact on prescription supply for the same drug and, overall, there was a substantial increase in the supply of chloramphenicol in primary care in the first three years following reclassification. 17, 18 Whether this situation remained the same beyond three years is unknown. Secondly, there is increasing clinical evidence that topical antibiotics are of limited benefit in infective conjunctivitis in primary care. 19 Given that the condition is, in most cases, self-limiting 20, 21 and restricting use of antibiotics minimizes unnecessary treatment and emergence of resistance 22 , the current consensus in managing these patients is to adopt the practice of 'no or delayed antibiotic' supply 23 . Recent evidence suggests this may have impacted on the prescribing of ophthalmic chloramphenicol by GPs 24 but whether supply OTC was affected remains unclear.
The aims of the study, therefore, were to (i) quantify the sales of OTC ophthalmic chloramphenicol from all community pharmacies in Wales and investigate the impact on primary care prescriptions up to five years after reclassification and (ii) investigate the temporal relationship between items supplied OTC and on NHS primary care prescriptions.
METHOD
The study had an ecological design and involved a retrospective analysis of prescription data and OTC sales data for ophthalmic chloramphenicol supplied in Wales. 
Prescription and OTC supply
The total number of items supplied on prescription or sold OTC are presented as the 12-month totals for the eye drops, from June to May, and for the ointment, from July to June, to allow the comparison before and after their respective availability OTC. Correlation coefficient (r) for prescription items supplied and OTC sales of combined chloramphenicol eye drops and ointment was calculated using Spearman's rank correlation, based on actual prescribing and OTC sales data between January 2008 and December 2010.
All data analysis and statistics were performed using PASW version 18 (SPSS Inc., Chicago, IL, USA).
RESULTS
The linear regression model generated cumulative sales equations for eye drops (R A summary of the combined quantities of eye drops and ointment sold OTC or supplied on prescription is shown in Figure 4 .
In the period January 2008 to December 2010, a marked seasonal variation for eye drops supplied on both prescription and sold OTC was observed, with peaks occurring between
December to March and nadirs between August to October each year. In comparison, the supply of the ointment showed no discernable seasonal variation ( Figure 5 ). Spearman's rank correlation revealed a significant and positive correlation between prescriptions and OTC sales of chloramphenicol eye drops and ointment combined (r=0.7, p<0.001).
DISCUSSION
The pharmacy sales data presented in this study are the first and the most comprehensive dataset studied to date and include data from all NHS-contracted community pharmacies in
Wales. The results demonstrate that the availability of ophthalmic chloramphenicol OTC has contributed to an increase in the supply of chloramphenicol greater than previously identified. 18 Supplies of OTC chloramphenicol eye drops increased from 2005 to 2007 but have subsequently remained stable. Similarly, the availability of OTC eye ointment increased overall use in primary care. It would appear that despite the relatively large quantity of ophthalmic chloramphenicol being sold OTC, it has had little or no impact on prescription supply some five years after it was reclassified to a P medicine. As a consequence there has been no cost saving on drug expenditure for the NHS as was initially expected. 26 When the temporal relationship between OTC sales of ophthalmic chloramphenicol and items dispensed on prescription was explored, it was found that there was a positive relationship.
This may, in part, suggest community pharmacists and primary care prescribers were responding to similar presenting symptoms but whether or not prescribing and/or OTC sales were appropriate is unclear.
Study Limitations
Primary care prescribing data was comprehensive, and extracted from an established and routinely used database that included details of NHS prescriptions dispensed by every community pharmacy in primary care in Wales. The OTC sales data were obtained from two sources: IMS Health and a pharmacy chain (Company A). Previous research noted that sales data collected by IMS Health only included 87% of all community pharmacies in Wales 18 and, as such, sales would underestimate the actual volume sold. In the present study, sales figures from Company A were obtained and complemented the IMS Health dataset. It should also be noted that two other branded products came to OTC market during the study. While data for these two products was not captured in the IMS Health dataset there appeared to be no impact on sales of the products monitored. Moreover we could identify the total amount of ophthalmic chloramphenicol prescribed and sold throughout the period of the study and this indicated sales of these new brands were negligible.
Unlike the IMS Health data, which were available for the entire post-reclassification period, sales data from Company A were only available from 2008 to 2010, and therefore the quantities sold during the first three years following OTC availability had to be estimated. It was possible that the sales pattern during the early months of a new product could have been markedly different. However, the available sales trend data from IMS Health for the other 614/708 community pharmacies in Wales indicated this was not an issue.
An important difference between the pharmacy sales data utilized in the present study is that while data from Company A represented transactions between pharmacy and customers, IMS Health data reported supplies from wholesalers to pharmacies. As with previous studies that have employed IMS Health sales data 18, 24 , the latter was identified to be a good proxy for pharmacy-to-customer sales. This relationship is likely to hold for chloramphenicol eye drops as they need to be stored in a fridge, where space is usually at a premium, and bulk advance purchases unlikely. Advanced ordering in anticipation of increased demand associated with, for example, an upcoming advertising campaign, and/or bulk-purchase discount offers would have distorted sales figures but we have no evidence this was the case over the study period monitored.
The present study was limited by its ecological nature, and consequently we were unable to identify factors that caused the increased and sustained supply of ophthalmic chloramphenicol OTC. It was likely that the removal of barriers such as the need to make a GP appointment, improved access and cost of travelling to and from doctor's surgery provided sufficient incentive for people to practice self-care 3 , even if individuals had to purchase the treatment themselves in a country with no co-payment prescription levy. Sales could have been stimulated by promotional activities and, as a result, improved the public's awareness of conjunctivitis and product availability. Although there was a temporal relationship between OTC sales and items supplied on prescription, suggesting that patients with similar presentations were turning up at both community pharmacies and GP surgeries and were supplied ophthalmic chloramphenicol. This result needs to be interpreted with caution as it only serves to demonstrate an association between the two variables rather than providing an explanation for them. To date there has been no published data that has evaluated the appropriateness of prescribing or OTC supply of ophthalmic chloramphenicol in primary care, even if such criteria could be defined.
Comparison with literature
Contrary to the trend of reduced prescribing for ophthalmic chloramphenicol reported in in Wales, there was a small but distinguishable increase in eye drops dispensed on prescription, which is consistent with the observation made by others of an increase in prescription items following abolition of the co-payment charge. 27 This was not observed with the ointment over the same period but is probably because the market had not matured or stabilized. It has been suggested that the decrease in the number of items prescribed for chloramphenicol eye drops and ointment in England was due to a change in the management of conjunctivitis from empirical prescribing to no or delayed prescribing. 24 Whether or not prescribers in Wales adopted this approach is unknown. Moreover, changes in prescriber preference, such as switching from one topical ophthalmic antibiotic to another may have confounded the picture. 
IMPLICATIONS
When ophthalmic chloramphenicol was reclassified in the UK, concerns were raised about the possibility of misdiagnosis 16 
CONCLUSION
Over the five-year study period, there was an increase in overall supply of ophthalmic chloramphenicol following availability from community pharmacies without prescription. The initial year-on-year increase in overall supply reported by others 17, 24 appears to have stabilized four years post-reclassification while having little impact on prescription items over the entire study period. Despite a temporal relationship between OTC ophthalmic chloramphenicol supply and items dispensed on prescription, the appropriateness of supplies from community pharmacies remains unknown. The benefits and risks of having ophthalmic chloramphenicol available OTC and the impact of updated practice guidance on its prescribing OTC need to be studied further to better understand its current, high level of use.
